Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Parallel evolution of HIV-1 in a long-term experiment.

Bertels F, Leemann C, Metzner KJ, Regoes R.

Mol Biol Evol. 2019 Jun 28. pii: msz155. doi: 10.1093/molbev/msz155. [Epub ahead of print]

PMID:
31251344
2.

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.

Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel CD, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun DL, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

J Infect Dis. 2019 Jun 19;220(2):254-265. doi: 10.1093/infdis/jiz094.

PMID:
30835266
3.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study.

Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

PMID:
30202088
4.

MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.

Huber M, Metzner KJ, Geissberger FD, Shah C, Leemann C, Klimkait T, Böni J, Trkola A, Zagordi O.

J Virol Methods. 2017 Feb;240:7-13. doi: 10.1016/j.jviromet.2016.11.008. Epub 2016 Nov 17.

5.

Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.

Giallonardo FD, Töpfer A, Rey M, Prabhakaran S, Duport Y, Leemann C, Schmutz S, Campbell NK, Joos B, Lecca MR, Patrignani A, Däumer M, Beisel C, Rusert P, Trkola A, Günthard HF, Roth V, Beerenwinkel N, Metzner KJ.

Nucleic Acids Res. 2014 Aug;42(14):e115. doi: 10.1093/nar/gku537. Epub 2014 Jun 27.

6.

Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination.

Di Giallonardo F, Zagordi O, Duport Y, Leemann C, Joos B, Künzli-Gontarczyk M, Bruggmann R, Beerenwinkel N, Günthard HF, Metzner KJ.

PLoS One. 2013 Sep 18;8(9):e74249. doi: 10.1371/journal.pone.0074249. eCollection 2013.

7.

Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.

Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2013 Oct 1;208(7):1102-12. doi: 10.1093/infdis/jit310. Epub 2013 Jul 11.

8.

Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant.

Bansal V, Metzner KJ, Niederost B, Leemann C, Boni J, Gunthard HF, Fehr JS.

Emerg Infect Dis. 2011 Oct;17(10):1966-8. doi: 10.3201/eid1710.110592. No abstract available.

9.

Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.

Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, Niederöst B, Leemann C, Gianella S, Metzner KJ, Böni J, Weber R, Günthard HF.

Clin Infect Dis. 2011 Dec;53(12):1271-9. doi: 10.1093/cid/cir725. Epub 2011 Oct 12.

10.

Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Guenthard HF.

PLoS One. 2011;6(7):e21734. doi: 10.1371/journal.pone.0021734. Epub 2011 Jul 6.

11.

HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men.

Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Böni J, Yerly S, Klimkait T, Bürgisser P, Weber R, Fischer M, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2010 May 15;24(8):1177-83. doi: 10.1097/QAD.0b013e328338e4de.

PMID:
20386427
12.

Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.

Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, Böni J, Weber R, Günthard HF.

J Infect Dis. 2010 Apr 1;201(7):1063-71. doi: 10.1086/651136.

13.

In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.

Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF.

J Virol. 2008 Feb;82(3):1591-9. Epub 2007 Nov 21.

14.

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederöst B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A.

J Virol. 2007 Aug;81(16):8793-808. Epub 2007 Jun 13.

15.

First case of bacteremia and multifocal cellulitis due to Helicobacter canis in an immunocompetent patient.

Leemann C, Gambillara E, Prod'hom G, Jaton K, Panizzon R, Bille J, Francioli P, Greub G, Laffitte E, Tarr PE.

J Clin Microbiol. 2006 Dec;44(12):4598-600. Epub 2006 Sep 27.

16.

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study.

J Virol. 2005 Jul;79(14):9026-37.

17.

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A.

J Virol. 2005 Jul;79(13):8454-69.

18.

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF.

Nat Med. 2005 Jun;11(6):615-22. Epub 2005 May 8.

PMID:
15880120
19.

Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.

Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Günthard HF, Trkola A.

Virology. 2004 Aug 15;326(1):113-29.

20.

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.

Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Furrer H, Battegay M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study.

Blood. 2004 Sep 15;104(6):1784-92. Epub 2004 Jun 8.

21.

Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF; Swiss HIV Cohot Study.

J Virol. 2003 Dec;77(24):13146-55.

22.

RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.

Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, Moore JP, Proudfoot AE, Trkola A.

Blood. 2003 Aug 15;102(4):1169-77. Epub 2003 Apr 24.

23.

Collective pinning of a frozen vortex liquid in ultrathin superconducting YBa2Cu3O7 films.

Calame M, Korshunov SE, Leemann C, Martinoli P.

Phys Rev Lett. 2001 Apr 16;86(16):3630-3.

PMID:
11328040
24.

Observation of domain-wall superlattice states in a frustrated triangular array of Josephson junctions.

Théron R, Korshunov SE, Simond JB, Leemann C, Martinoli P.

Phys Rev Lett. 1994 Jan 24;72(4):562-565. No abstract available.

PMID:
10056464
25.

Evidence for nonconventional vortex dynamics in an ideal two-dimensional superconductor.

Théron R, Simond J, Leemann C, Beck H, Martinoli P, Minnhagen P.

Phys Rev Lett. 1993 Aug 23;71(8):1246-1249. No abstract available.

PMID:
10055487
26.

Vortex dynamics in superconducting fractal networks.

Meyer R, Gavilano JL, Jeanneret B, Théron R, Leemann C, Beck H, Martinoli P.

Phys Rev Lett. 1991 Nov 18;67(21):3022-3025. No abstract available.

PMID:
10044618
27.

Percolative behavior of the superconductive transition of YBa2Cu3O7 films.

Leemann C, Flückiger P, Marsico V V, Gavilano JL, Srivastava PK, Lerch P, Martinoli P.

Phys Rev Lett. 1990 Jun 18;64(25):3082-3085. No abstract available.

PMID:
10041890
28.

Dynamics of the phase transition in proximity-effect arrays of Josephson junctions at full frustration.

Lerch P, Leemann C, Theron R, Martinoli P.

Phys Rev B Condens Matter. 1990 Jun 1;41(16):11579-11582. No abstract available.

PMID:
9993582
29.

Critical phase fluctuations in superconducting wire networks.

Jeanneret B, Flückiger P, Gavilano JL, Leemann C, Martinoli P.

Phys Rev B Condens Matter. 1989 Dec 1;40(16):11374-11377. No abstract available.

PMID:
9991721
30.

Vortex dynamics and phase transitions in a two-dimensional array of Josephson junctions.

Leemann C, Lerch P, Racine G, Martinoli P.

Phys Rev Lett. 1986 Mar 24;56(12):1291-1294. No abstract available.

PMID:
10032623
31.

Present and future sources of protons and heavy ions.

Grunder HA, Leemann CW.

Int J Radiat Oncol Biol Phys. 1977;3:71-80. No abstract available.

PMID:
96081
32.

[The laryngeal granuloma].

LEEMANN C.

Pract Otorhinolaryngol (Basel). 1959 Sep;21:381-6. German. No abstract available.

PMID:
14415228
33.

[Therapy of inflammations in otorhinolaryngology with penisulfa].

LEEMANN C.

Schweiz Med Wochenschr. 1952 Aug 2;82(31):795-6. Undetermined Language. No abstract available.

PMID:
12984062
34.

[A rare sarcomatous nasopharyngeal tumor].

LEEMANN C.

Pract Otorhinolaryngol (Basel). 1952;14(4-5):289-93. Undetermined Language. No abstract available.

PMID:
13026631

Supplemental Content

Loading ...
Support Center